Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.19.2
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 6 Months Ended
Mar. 06, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Disaggregation of Revenue [Line Items]          
Total revenue   $ 24,987 $ 90,043 $ 68,471 $ 146,200
Royalties          
Disaggregation of Revenue [Line Items]          
Total revenue   6,626 31,396 26,164 52,216
Promacta          
Disaggregation of Revenue [Line Items]          
Total revenue $ 14,200 0 24,806 14,193 40,379
Kyprolis          
Disaggregation of Revenue [Line Items]          
Total revenue   4,882 4,730 8,715 8,125
Evomela          
Disaggregation of Revenue [Line Items]          
Total revenue   1,144 1,160 2,055 2,760
Other          
Disaggregation of Revenue [Line Items]          
Total revenue   600 700 1,201 952
Material Sales: Captisol          
Disaggregation of Revenue [Line Items]          
Total revenue   8,549 7,612 17,508 12,003
License fees, milestones and other          
Disaggregation of Revenue [Line Items]          
Total revenue   9,812 51,035 24,799 81,981
License Fees          
Disaggregation of Revenue [Line Items]          
Total revenue   1,990 47,981 2,840 74,936
Milestone          
Disaggregation of Revenue [Line Items]          
Total revenue   4,175 1,919 16,107 4,744
Other          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 3,647 $ 1,135 $ 5,852 $ 2,301